Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ortivus ABLTS:0H1Q 44 EBITDA Margin % is -5.04% as of Mar. 2026. GuruFocus rates LTS:0H1Q with a GF Score™ of 44/100 and a GF Value™ of kr6.51. The stock has 3 warning signs investors should review. Among 814 Medical Devices & Instruments companies, Ortivus AB ranks worse than 73.1% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ortivus AB's EBITDA for the
three
months ended in Mar. 2026 was kr-1.08 Mil. Ortivus AB's Revenue for the
three
months ended in Mar. 2026 was kr21.49 Mil. Therefore, Ortivus AB's EBITDA margin for the quarter that ended in Mar. 2026 was -5.04%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ortivus AB EBITDA Margin % Related Terms
Ortivus AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ortivus AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0H1Q vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Ortivus AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ortivus AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ortivus AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ortivus AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ortivus AB (LTS:0H1Q) has a EBITDA Margin % of -5.04% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ortivus AB and its competitors. According to the industry distribution chart, Ortivus AB ranks #595 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 73.1%.
Is Ortivus AB's EBITDA Margin % too high?
Ortivus AB's current EBITDA Margin % is -5.04%. Based on the distribution chart, Ortivus AB ranks #595 out of 814 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ortivus AB has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Ortivus AB's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ortivus AB ranks #595 out of 814 companies for EBITDA Margin %. This places Ortivus AB in the lower half of its industry. The industry median EBITDA Margin % is 7.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.74, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ortivus AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ortivus AB's current EBITDA Margin % is -5.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortivus AB stock overvalued right now?
Ortivus AB (LTS:0H1Q) has a current EBITDA Margin % of -5.04%. The stock's GF Value™ is kr6.51, compared to a current price of kr5.10 — trading 21.7% below its estimated fair value. The current EBITDA Margin % is -5.04%. Ortivus AB's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ortivus AB (LTS:0H1Q), the current EBITDA Margin % is -5.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ortivus AB (LTS:0H1Q) Overvalued in 2026?
Based on GuruFocus' analysis, Ortivus AB stock appears to be undervalued.
The current stock price of kr5.10 is trading 21.7% below its estimated GF Value™ of kr6.51.
Key valuation signals for LTS:0H1Q:
EBITDA Margin %: -5.04%
GF Value™: kr6.51 vs. price of kr5.10 (21.7% below fair value)
No single metric tells the full story. See the LTS:0H1Q stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ortivus AB is a supplier of mobile solutions for modern emergency medical care. The company has developed an user-friendly solutions that supports diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating its solutions with electronic health records, dispatch systems, and national registries, the company ensures fast and secure information management and more integrated care process. Its product portfolio includes MobiMed ePR, MobiMed Monitor, MobiMed FleetCtrl, MobiMed Life, and others.
44GF Score
Get the complete analysis for LTS:0H1Q
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H1Q has been successfully added to your 
